


Statistical Report for AEFI COVID 19

The first Covid-19 vaccine has arrived in Rwanda on 3 March 2021 as the first batch of 240,000 doses of the AstraZeneca-Oxford vaccine. So far we are having two types of vaccines which are being used to defeat Covid-19. Below is the presentation of reported cases based on current vaccines.

Number of case reported per vaccine		Seriousness of case reported		
Vaccine name	# case reported	Vaccine name	Serious	Not serious
Pfizer	11	Astrazeneca	5	55
Astrazeneca	60	Pfizer	0	11
Total	71	Total	5	66

1. Distribution of 71 cases reported: Seriousness, Severity by vaccines name



2. Seriousness and corresponding severity

2.1. Serious cases and corresponding severity

Among the 5 serious cases reported, 4 of them are severe and 1 Moderate. All 5 cases are Astrazeneca vaccine based report.

The five serious cases showed the following description:

Description	Vaccine	Sex	age	Cases	severity
1.Hypertension and respiratory distress	AstraZeneca	F	48	1	Severe
2.Respiratory Distress	AstraZeneca	F	31	1	Severe
3.Headache, dizziness, tongue protrusion out, rigidity and mouth limitation movement	AstraZeneca	M	65	1	Severe
4.General body weakness, nausea, dizziness, check pain, cardiac palpitation and dyspnea, BP:164/107mmHg, T° 36.7 and SOP <sub>2</sub> :96% :	AstraZeneca	M	42	1	Moderate
5.severe headache, body weakness ,nausea , vomiting , dry cough , joint pain and swelling & painful at site of injection, Headache and loss of appetite	AstraZeneca	F	37	1	Severe

3. Summary of High Frequent cases and description

- 67% of Pfizer vaccine case reported and 10% of AstraZeneca vaccine cases reported are experiencing **dizziness** but not at serious level.
- 16% of AstraZeneca vaccine cases reported are experiencing **Headache** but not at serious level. No headache with Pfizer vaccine
- 80% of Pfizer vaccine cases reported are experiencing **body weakness** with palpitation and dizziness but not at serious level. However 11.9% of AstraZeneca vaccine cases reported are experiencing body weakness with high blood pressure and sneezing but not at serious level.
- 8.5% of AstraZeneca vaccine cases reported with serious level are **experiencing Hypertension, respiratory distress**, headache and dizziness, tongue protrusion out, rigidity, mouth limitation movement, **check pain**, cardiac palpitation and dyspnea, severe headache, **body weakness**, nausea , vomiting , dry cough , joint pain and swelling & painful at site of njection, Headache and loss of appetite

2.2. Not Serious Cases and corresponding severity

Among the 66 none serious cases reported: 11 are Pfizer vaccine based with following severity: ( 8 cases Moderate, 2 case severe and 1 mild).

2.2.A. Pfizer; Description of none serious cases

In the eleven none serious case reported for Pfizer vaccine , 73% are aged between 30 and 40, 9% are under 30, 9% greater than 45 another 9% are unknown age as summarized in below table:

Description	Vaccine	Sex	age	Cases	severity
1. Dizziness, heavy legs, palpitation, body weakness associated with shivering	Pfizer	M	39	2	Moderate
2. Chest pain	Pfizer	M	33	1	Mild
3. Dizziness, palpitations, body weakness associated with shivering	Pfizer	M	34	1	Severe
			39	1	Moderate
		Unknown	34	1	Moderate
			Unknown	1	Moderate
			36	1	Moderate
4. Dizziness, nausea, and headache	Pfizer	Unknown	32	1	Moderate
5. Generalized body weakness	Pfizer	M	28	1	Severe
		F	49	1	Severe

2.2.B. AstraZeneca; Description of none serious cases

fitfty-five none serious cases reported for AstraZeneca vaccine with following severity: ( 12 severe, 33 Moderate, and 10 mild).